NASDAQ:NKTX

Nkarta (NKTX) Stock Price, News & Analysis

Nkarta logo
$1.14 +0.02 (+1.34%)
Closing price 04:00 PM Eastern
Extended Trading
$1.12 -0.01 (-1.32%)
As of 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Nkarta Stock (NASDAQ:NKTX)

Advanced

Key Stats

Today's Range
$1.11
▼
$1.22
50-Day Range
$1.12
▼
$2.95
52-Week Range
$1.11
▼
$3.72
Volume
1.60 million shs
Average Volume
1.70 million shs
Market Capitalization
$81.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.20
Consensus Rating
Moderate Buy

Company Overview

Nkarta, Inc. is a clinical-stage biotechnology company developing cell therapies based on natural killer (NK) cells, immune cells that can identify and attack abnormal cells. The company’s approach uses donor-derived NK cells that are engineered to recognize cancer targets and intended for use as off-the-shelf treatments.

Nkarta’s research programs have included NKX019, an engineered NK-cell therapy targeting CD19, a protein found on certain B-cell cancers, and NKX101, designed to recognize stress signals on cancer cells. These are investigational therapies, and the company does not have approved commercial products.

Founded in 2015, Nkarta is based in South San Francisco, California. Its development work has focused on potential treatments for blood cancers, including B-cell malignancies and acute myeloid leukemia.

AI Generated. May Contain Errors.

Nkarta Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
68th Percentile Overall Score

NKTX MarketRank™: 
3.390867831105 of 5 stars

Nkarta scored higher than 68% of companies evaluated by MarketBeat, and ranked 281st out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Nkarta has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 1 strong buy rating, 5 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Nkarta has a consensus price target of $11.20, representing about 886.8% upside from its current price of $1.14.

  • Amount of Analyst Coverage

    Nkarta has only been the subject of 3 research reports in the past 90 days.

  • Read more about Nkarta's stock forecast and price target.
  • Earnings Growth

    Earnings for Nkarta are expected to grow in the coming year, from ($1.67) to ($1.25) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Nkarta is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Nkarta is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Nkarta has a P/B Ratio of 0.38. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    5.94% of the float of Nkarta has been sold short.
  • Short Interest Ratio / Days to Cover

    Nkarta has a short interest ratio ("days to cover") of 2.87, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Nkarta has recently increased by 12.14%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Nkarta does not currently pay a dividend.

  • Dividend Growth

    Nkarta does not have a long track record of dividend growth.

  • News Sentiment

    Nkarta has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Nkarta this week, compared to 2 articles on an average week.
  • Search Interest

    9 people have searched for NKTX on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Nkarta to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Nkarta insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    9.80% of the stock of Nkarta is held by insiders.

  • Percentage Held by Institutions

    80.54% of the stock of Nkarta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Nkarta's insider trading history.
Receive NKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nkarta and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NKTX Stock News Headlines

Nkarta, Inc. (NKTX) - What Are Researchers Thinking About This Stock?
What is HC Wainwright's Forecast for Nkarta FY2026 Earnings?
URGENT: If you own a home, please review the map below.
More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it.tc pixel
Nkarta (NASDAQ:NKTX) Earns "Buy" Rating from Needham & Company LLC
See More Headlines

NKTX Stock Analysis - Frequently Asked Questions

Nkarta's stock was trading at $1.85 on January 1st, 2026. Since then, NKTX stock has decreased by 38.6% and is now trading at $1.1350.

Nkarta, Inc. (NASDAQ:NKTX) issued its quarterly earnings results on Tuesday, November, 10th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.40) by $0.05.

Nkarta (NKTX) raised $231 million in an initial public offering on Friday, July 10th 2020. The company issued 14,000,000 shares at a price of $16.00-$17.00 per share. Cowen, Evercore ISI, Stifel and Mizuho Securities served as the underwriters for the IPO.

Top institutional shareholders of Nkarta include State Street Corp (1.84%), Marshall Wace LLP (0.85%), Goldman Sachs Group Inc. (0.48%) and Empowered Funds LLC (0.15%). Insiders that own company stock include Paul J Hastings, Nadir Mahmood, James Trager and Alicia J Hager.
View institutional ownership trends
.

Shares of NKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nkarta investors own include Micron Technology (MU), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Editas Medicine (EDIT), Gossamer Bio (GOSS) and Heron Therapeutics (HRTX).

Company Calendar

Last Earnings
11/10/2026
Today
11/20/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:NKTX
CIK
1787400
Fax
N/A
Employees
103
Year Founded
2015

Price Target and Rating

High Price Target
$14.00
Low Price Target
$9.00
Potential Upside/Downside
+886.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.73)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$104.08 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-48.58%
Return on Assets
-36.26%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.79
Quick Ratio
5.79

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.01 per share
Price / Book
0.38

Miscellaneous

Outstanding Shares
71,700,000
Free Float
64,677,000
Market Cap
$81.38 million
Optionable
Optionable
Beta
1.24

Social Links

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

This page (NASDAQ:NKTX) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners